ASX Announcements 2018

Date Document
11/12/2018 Response to ASX Price and Volume Query
03/12/2018 FDA Clearance Granted for FerriSmart
20/11/2018 R&D Tax Incentive
16/11/2018 Change of Director's Interest Notice
08/11/2018 Results of Meeting
08/11/2018 AGM Presentation
31/10/2018 New Work Order to provide services for Clinical Trial
29/10/2018 Appendix 4C - quarterly
23/10/2018 Response to ASX Price and Volume Query
23/10/2018 Pause in Trading
08/10/2018 Notice of Annual General Meeting/Proxy Form
08/10/2018 Annual Report to shareholders
14/09/2018 Amended Appendix 3B
13/09/2018 Appendix 4G and Corporate Governance Statement
13/09/2018 Full Year Statutory Accounts
13/09/2018 Appendix 3B
06/09/2018 Change of Substantial Shareholder Notification
06/09/2018 Change of Director's Interest Notice
30/08/2018 Preliminary Final Report
27/08/2018 Additional Information on Announcement Dated 23 August 2018
27/08/2018 Trading Halt
23/08/2018 Resonance Health contracted for two new clinical trials
23/07/2018 Appendix 4C - quarterly
11/07/2018 TGA, CE Mark clearance for A.I. Solution FerriSmart
05/07/2018 Alliance Partner Agreement with Blackford Analysis
29/06/2018 Customer Newsletter - June 2018
12/06/2018 Investor Presentation June 2018
31/05/2018 Change of Director's Interest Notice
29/05/2018 Change of Director's Interest Notice
04/05/2018 Additional Info. in relation to 4 May 2018 announcement
04/05/2018 Resonance Deal to distribute Diabetic Retinopathy AI tool
23/04/2018 Appendix 4C - quarterly
23/03/2018 Customer Newsletter - March 2018
09/03/2018 Appendix 3B
07/03/2018 Change of Director's Interest Notice
28/02/2018 Director Appointment
26/02/2018 Half Yearly Report and Accounts
23/02/2018 Appointment of CEO
20/02/2018 RHT Develops new assessment for the screening of NASH
15/02/2018 Change of Director's Interest Notice
13/02/2018 Resonance Health contracted for new clinical trial
09/02/2018 R&D Tax Incentive
31/01/2018 Appendix 4C - quarterly
12/01/2018 FerriScan contracted for two new Clinical Trials